Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
www.forbes.com
October 1, 2025 at 10:40 AM
Herriot Tabuteau combined his Yale medical degree and two decades in finance to start Axsome Therapeutics. Now the company has three drugs on the market and five more in the pipeline.
here are the others:
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
September 19, 2025 at 6:34 PM
here are the others:
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
Yes on 50 campaign (twice)
Vraylar anti depressant (Abbvie)
Auvelity anti depressant (Axsome Therapeutics)
The law offices of Larry H. Parker
Covered California
U.S. Air Force
Jacoby & Meyers
Sweet James accident attorneys (twice)
Alaskans own 35,396 shares of Axsome Therapeutics Inc worth $4,128,235. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
July 12, 2025 at 2:01 AM
Alaskans own 35,396 shares of Axsome Therapeutics Inc worth $4,128,235. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
Axsome might have potential, but let’s be real—if you're not analyzing the leadership structure and how much woke HR is embedded in the company, you're missing the real investment risk. I’ll stick with founders who build, not placate.
May 19, 2025 at 1:14 PM
Axsome might have potential, but let’s be real—if you're not analyzing the leadership structure and how much woke HR is embedded in the company, you're missing the real investment risk. I’ll stick with founders who build, not placate.
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
https://www.newsbeep.com/il/49189/
Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help…
https://www.newsbeep.com/il/49189/
Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help…
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s - Israel News Beep
Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help some 150 million Americans suffering from brain
www.newsbeep.com
October 1, 2025 at 2:20 PM
This Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’s
https://www.newsbeep.com/il/49189/
Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help…
https://www.newsbeep.com/il/49189/
Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help…
Axsome settles… https://news.google....
February 10, 2025 at 2:48 PM
Axsome settles… https://news.google....
Thoughts on this? >> Axsome reports Phase 3 depression fail for Sunosi >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #biotech #pharma
Axsome reports Phase 3 depression fail for Sunosi
Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major depressive disorder. The company was testing Sunosi in patients who had MDD with ...
dlvr.it
April 1, 2025 at 3:35 PM
Thoughts on this? >> Axsome reports Phase 3 depression fail for Sunosi >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #biotech #pharma
Kuehn Law Investigates Potential Misrepresentation at Axsome Therapeutics#USA#New_York#Kuehn_Law#Axsome_Therapeutics#AXSM
Kuehn Law Investigates Potential Misrepresentation at Axsome Therapeutics
Kuehn Law is looking into possible fiduciary breaches by Axsome Therapeutics' officers and directors, specifically regarding misrepresentations about the company's product prospects.
third-news.com
April 8, 2025 at 6:14 PM
Kuehn Law Investigates Potential Misrepresentation at Axsome Therapeutics#USA#New_York#Kuehn_Law#Axsome_Therapeutics#AXSM
Axsome Therapeutics (NASDAQ:AXSM) Upgraded at Cantor Fitzgerald Cantor Fitzgerald upgraded shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) to a strong-buy rating in a research note released on Wednesday,Zacks.com reports. Several other resea...
| Details | Interest | Feed |
| Details | Interest | Feed |
Origin
reporter.am
May 17, 2025 at 6:25 AM
These are the key earnings to watch this week: Not the full list, just the ones that could move markets.
Monday: Palantir ( $PLTR ), Wayfair ( $W ), Tyson Foods ( $TSN ), Axsome ( $AXSM )
Tuesday: Pfizer ( $PFE ), Caterpillar ( $CAT ), BP ( $BP ), AMD ( $AMD ), DuPont ( $DD ), Snap ( $SNAP ),
Monday: Palantir ( $PLTR ), Wayfair ( $W ), Tyson Foods ( $TSN ), Axsome ( $AXSM )
Tuesday: Pfizer ( $PFE ), Caterpillar ( $CAT ), BP ( $BP ), AMD ( $AMD ), DuPont ( $DD ), Snap ( $SNAP ),
August 3, 2025 at 3:05 PM
These are the key earnings to watch this week: Not the full list, just the ones that could move markets.
Monday: Palantir ( $PLTR ), Wayfair ( $W ), Tyson Foods ( $TSN ), Axsome ( $AXSM )
Tuesday: Pfizer ( $PFE ), Caterpillar ( $CAT ), BP ( $BP ), AMD ( $AMD ), DuPont ( $DD ), Snap ( $SNAP ),
Monday: Palantir ( $PLTR ), Wayfair ( $W ), Tyson Foods ( $TSN ), Axsome ( $AXSM )
Tuesday: Pfizer ( $PFE ), Caterpillar ( $CAT ), BP ( $BP ), AMD ( $AMD ), DuPont ( $DD ), Snap ( $SNAP ),
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest: Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
news.google.com
September 2, 2025 at 5:55 AM
Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience - AInvest: Axsome Therapeutics: Fortifying Market Dominance Through Strategic Patent Portfolios and Franchise Resilience AInvest
Axsome moving forward with Phase III in depression despite study miss $AXSM firstwordpharma.com/story/5946631
April 1, 2025 at 9:35 PM
Axsome moving forward with Phase III in depression despite study miss $AXSM firstwordpharma.com/story/5946631
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News: Axsome and Hetero settle patent fight over sleep disorder drug Endpoints News
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News
Axsome and Hetero settle patent fight over sleep disorder drug Endpoints News
news.google.com
May 27, 2025 at 6:53 PM
Axsome and Hetero settle patent fight over sleep disorder drug - Endpoints News: Axsome and Hetero settle patent fight over sleep disorder drug Endpoints News
NEWS: ( NASDAQ: #AXSM ) Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
#StockMarket #News
#StockMarket #News
September 4, 2024 at 5:25 PM
摩根士丹利发布Axsome Therapeutics（AXSM）增持评级，展望未来增长潜力
https://qian.cx/posts/C3221D48-2E19-44B9-BA7E-666D11B1BC8E
https://qian.cx/posts/C3221D48-2E19-44B9-BA7E-666D11B1BC8E
October 12, 2025 at 4:55 AM
摩根士丹利发布Axsome Therapeutics（AXSM）增持评级，展望未来增长潜力
https://qian.cx/posts/C3221D48-2E19-44B9-BA7E-666D11B1BC8E
https://qian.cx/posts/C3221D48-2E19-44B9-BA7E-666D11B1BC8E
Alaskans own 42,058 shares of Axsome Therapeutics Inc worth $4,390,435. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
August 30, 2025 at 6:30 AM
Alaskans own 42,058 shares of Axsome Therapeutics Inc worth $4,390,435. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
#AXSM Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-9ckbohm5635b.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-9ckbohm5635b.html
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, announced that CEO Herriot Tabuteau and the management team will ring the NASDAQ opening bell on July 21, 2025. The ceremony coincides with their Frontiers in Brain Health R&D Day event.The event highlights Axsome's progress in developing late-stage CNS product candidates and celebrates the recent U.S. launch of SYMBRAVO®. The company aims to transform clinical practice in brain health through its portfolio of marketed medicines and investigational treatments for CNS conditions. The bell ringing ceremony will be held at the Nasdaq MarketSite in Times Square, New York, starting at 9:20 a.m. ET.
www.stocktitan.net
July 21, 2025 at 11:00 AM
#AXSM Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-9ckbohm5635b.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-to-ring-the-nasdaq-stock-market-opening-bell-9ckbohm5635b.html
https://www.fool.com/investing/2025/05/14/is-axsome-therapeutics-stock-worth-the-risk-a-comp/?source=askdougpancakes&utm;_source=chromefollow&utm;_medium=feed&utm;_campaign=news&referring;_guid=4c1e80e2-b091-4cc1-9b05-805092a83b75
#AXSM […]
[Original post on fool.com]
Original post on fool.com
www.fool.com
May 14, 2025 at 11:56 PM
Thoughts on this? >> Avidity to seek accelerated approval for FSHD drug; Axsome
to run another trial >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
to run another trial >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
Avidity to seek accelerated approval for FSHD drug; Axsome
to run another trial
Plus, news about Mosanna Therapeutics, Concentra Biosciences, Elevation Oncology, Keros, TuHURA Biosciences and PolyPid: Avidity Biosciences says FDA is open to accelerated approval for FSHD drug: The RNA drug company
dlvr.it
June 9, 2025 at 3:09 PM
Thoughts on this? >> Avidity to seek accelerated approval for FSHD drug; Axsome
to run another trial >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
to run another trial >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
Axsome Therapeutics Crushes Estimates with 72% Revenue Growth, Accelerating Path to Profitability https://signalbloom.ai/news/AXSM/axsome-therapeutics-crushes-estimates-with-72-revenue-growth-accelerating-path-to-profitability $AXSM #Earnings via @signalbloom.ai
August 4, 2025 at 11:48 AM
Axsome Therapeutics Crushes Estimates with 72% Revenue Growth, Accelerating Path to Profitability https://signalbloom.ai/news/AXSM/axsome-therapeutics-crushes-estimates-with-72-revenue-growth-accelerating-path-to-profitability $AXSM #Earnings via @signalbloom.ai
Axsome Therapeutics ($AXSM) reported EPS of -0.47(Adj) beating estimate of -1.06 for Q2 2025. Revenue 150.042 Million Vs 139.103564 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
August 4, 2025 at 11:06 AM
Axsome Therapeutics ($AXSM) reported EPS of -0.47(Adj) beating estimate of -1.06 for Q2 2025. Revenue 150.042 Million Vs 139.103564 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
#AXSM Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-availability-of-symbravo-meloxicam-and-yts7olgc6nom.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-availability-of-symbravo-meloxicam-and-yts7olgc6nom.html
Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways
Novel migraine treatment SYMBRAVO offers rapid pain relief through multi-mechanistic approach. See how this new FDA-approved therapy helps restore normal functioning. Learn more.
www.stocktitan.net
June 10, 2025 at 11:00 AM
#AXSM Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-availability-of-symbravo-meloxicam-and-yts7olgc6nom.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-announces-availability-of-symbravo-meloxicam-and-yts7olgc6nom.html
Alaskans own 42,058 shares of Axsome Therapeutics Inc worth $4,390,435. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
August 19, 2025 at 4:29 PM
Alaskans own 42,058 shares of Axsome Therapeutics Inc worth $4,390,435. It's in the 💊 Pharmaceuticals, Biotechnology&Life Sciences industry, based in 🇺🇸 United States.
Morgan Stanley начинает покрытие Axsome Therapeutics с рекомендацией «перевес» и ценовым ориентиром $190
https://kripta.biz/posts/14962F6B-6341-4245-89A4-7650C4529C35
https://kripta.biz/posts/14962F6B-6341-4245-89A4-7650C4529C35
October 12, 2025 at 4:56 AM
Morgan Stanley начинает покрытие Axsome Therapeutics с рекомендацией «перевес» и ценовым ориентиром $190
https://kripta.biz/posts/14962F6B-6341-4245-89A4-7650C4529C35
https://kripta.biz/posts/14962F6B-6341-4245-89A4-7650C4529C35